1.Study and exploration of the teaching experiment system of clinical skills
Chinese Journal of Medical Education Research 2005;0(06):-
To the situation that the students of TCM is not good at clinical skill,this article analyzed the reasons of this situation and put forward several suggestions including building the clinical experience subject system,experimental resources,teaching monitoring system and the experimental base.
2.Determination of the Contents in Compound Furacilin Nasal Drops by RP-HPLC
China Pharmacy 2001;0(07):-
OBJECTIVE:A RP-HPLC method to determine the contents of furacilin and ephedrine hydrochloride in compound furacilin nasal drops was established METHODS:Chromatographic detection was performed with a mixture of methanol-water-triethylamine-acetic acid(12∶88∶0 2∶1) as mobile phase and Kromasil C18(4 6mm?250mm,5?m) as separate column Chloramphenicol was selected as internal standard and the detection wavelength was 254nm RESULTS:The ingredients of compound furacilin nasal drops and internal standard were well separated within 18min Good linearities and recoveries for furacilin and ephedrine hydrochloride were obtained in their assay ranges CONCLUSION:The RP-HPLC method was found to be simple,accurate and suitable for the quality control of compound furacilin nasal drops
3.Comparative Study on the Chiral Pharmacokinetics of Amlodipine Enantiomers of Rabbits in Vivo
Jing LIU ; Xiangfei XING ; Guilan JIN
China Pharmacy 2005;0(17):-
0.05)and the main pharmacokinetic parameters were close to each other.CONCLUSION:No stereoselective differences lies in the pharmacokinetics processe of amlodipine enatiomers in the body of rabbits.
4.Preparation and Quality Control of Ganciclovir Hydrochloride Chitosan Eye Drops
Wei XI ; Guilan JIN ; Xiangfei XING
China Pharmacy 2001;0(10):-
OBJECTIVE:To prepare ganciclovir hydrochloride chitosan eye drops and establish its quality control method.METHODS:The eye drops was prepared using chitosan as thickening agent and synergist with ganciclovir as principal agent.The content of ganciiclovir was determined by HPLC.The stability of the preparation was investigated as well.RESULTS:The prepared eye drops was colorless transparent glutinous limpid liquid with its identification items all up to the related standards stipulated in Chinese Pharmacopoeia(2005 edition).The linear range of ganciclovir was 5~80 mg?L-1(r=0.999 9) with average recovery of 99.02%(RSD=0.71%).The preparation was stable under light with all its indexes showed no obvious change in the accelerated test at 6 month.CONCLUSION:The preparation technology is simple and feasible and the quality of preparation is stable and controllable with a validity duration tentatively set at 2 years.
5.Bioequivalence of 2 Kinds of Ganciclovir Eye Drops in Rabbits' Eyes
Guilan JIN ; Wei XI ; Xiangfei XING
China Pharmacy 2005;0(13):-
OBJECTIVE: To compare the pharmacokinetics and relative bioavailability between ganciclovir-chitosan eye drops and ganciclovir eye drops in rabbit eyes. METHODS: Japan big-eared rabbits were randomly assigned to the receive 50 ?L ganciclovir-chitosan eye drops (experiment group) or ganciclovir eye drops (control group) in both eyes. The rabbit tears,corneas and aqueous humor were collected at different time for the determination of drug concentration by RP-HPLC. The pharmacokinetics parameters were calculated as well. RESULTS: In the experimenal group,the half-life(t1/2) in tears,corneas and aqueous humor were 15.41,45.21,59.43 minutes,respectively versus 16.22,32.55,and 48.53 minutes in the control group. The Cmax were 2.03 ?g?mL-1 and 1.22 ?g?mL-1,respectively. In the experimental group,the AUC0→240 in tears,corneas and aqueous humor were 1.66,1.89,and 2.77 times those in control group. CONCLUSION: The bioavailability of ganciclovir-chitosan eye drops was significantly higher than that of ganciclovir eye drops.
6.Practice of Clinical Pharmacists Participating in the Treatment of One COPD Patient with Pulmonary In-fection
Yuanbin YAO ; Yan LOU ; Guilan JIN
China Pharmacist 2014;(11):1921-1924
Objective:To discuss the choice of anti-infective drugs and the significance of pharmaceutical care for COPD patients with pulmonary infection. Methods:Clinical pharmacists performed pharmaceutical care for a COPD patient with pulmonary infection including such aspects as drug selection, treatment course, drug interaction, adverse reactions and so on. Results:By providing phar-maceutical care for the patient, the problems in the treatment were identified and solved in time, and the rationality of drug treatment was improved. Conclusion:By participating in clinical practice, clinical pharmacists can assist physicians in improving the safety and efficacy of drug treatment and providing pharmaceutical care for patients.
7.Efficacy of Qijiao Shengbai Capsule in the Adjuvant Treatment of Leucopenia:A Meta-analysis
Wen TANG ; Jianling TAN ; Liangliang JIA ; Guilan JIN
China Pharmacy 2015;26(33):4672-4674
OBJECTIVE:To systematically review the efficacy of Qijiao shengbai capsule in the adjuvant treatment of leukope-nia,and provide evidence-based reference for the clinical treatment. METHODS:Retrieved from CJFD,VIP,Wanfang Database and Medline and EMBase,randomized controlled trials(RCT) about the efficacy of Qijiao shengbai capsule (test group) versus blank control(control group) in the adjuvant treatment of leucopenia were collected. Meta-analysis was performed by using Rev Man 5.2 software after the quality assessment and data extraction. RESULTS:A total of 15 RCTs were included,involving 1 383 patients. Results of Meta-analysis showed the total effective rate [OR=0.31,95%CI(0.23,0.43),P<0.001],obvious effective rate [OR=0.31,95%CI(0.24,0.41),P<0.001],leukocyte count [MD=-1.04,95%CI(-1.10,-0.98),P<0.001] and myelosuppres-sion reduction [OR=0.27,95%CI(0.14,0.52),P<0.001] in test group were significantly higher than control group,there were sig-nificant differences. Only 9 patients had adverse reactions of mild diarrhea,nausea and other symptoms,and it relieved after symp-tomatic treatment. CONCLUSIONS:Qijiao shengbai capsule has achieve good efficacy in the adjuvant treatment of leukopenia. Due to the limits of quality and sample size,more strict designed,long-term follow-up of large scale RCTs are needed for the fur-ther verification of the conclusion.
8.Effectiveness and Safety of Yinzhihuang Oral Liquid in the Adjuvant Treatment of Neonatal Jaundice:A Sys-tematic Review
Wen TANG ; Jianling TAN ; Liangliang JIA ; Guilan JIN
China Pharmacy 2016;27(12):1638-1641
OBJECTIVE:To systematically review the effectiveness and safety of Yinzhihuang oral liquid in the adjuvant treat-ment of neonatal jaundice,and provide evidence-based reference for clinical treatment. METHODS:Retrieved from CJFD,VIP Da-tabase,Wanfang Database,Medline and EMBase,randomized controlled trials(RCT)about the effectiveness of Yinzhihuang oral liquid(test group)based on the canventional treatment(control group)in the adjuvant treatment of neonatal jaundice were collect-ed,and Meta-analysis was performed by using Rev Man 5.2 software after data extracting and quality evaluating by modified Jadad. RESULTS:Totally 12 RCTs were enrolled,involving 1585 patients. Results of Meta-analysis showed total effective rate [OR=0.19,95%CI(0.12,0.30),P<0.001],serum total bilirubin levels [MD=-40.78,95%CI(-42.68,-38.89),P<0.001] and time of bilirubin decreased to normal [MD=-2.56,95%CI(-2.72,-2.40),P<0.001] in test group were significantly better than control group,the differences were statistically significant between 2 groups;3 reports of adverse reactions showed scme children had vomiting and mild diarrhea,they were improved after symptomatic treatment,and it did not affect the treatment. CONCLU-SIONS:The effectiveness of Yinzhihuang oral liquid is good in the adjuvant treatment of neonatal jaundice,with mild adverse reac-tions.
9.Efficacy of Yixinshu Capsule in the Adjuvant Treatment of Angina Pectoris:A Meta-analysis
Wen TANG ; Jianling TAN ; Liangliang JIA ; Guilan JIN
China Pharmacy 2016;27(3):351-353
OBJECTIVE:Tosystematically evaluate the efficacy of Yixinshu capsule in the adjuvant treatmentof angina pecto-ris,and provide evidence-based reference for clinical treatment. METHODS:Retrieved from CJFD,VIP Database,Wanfang Data-base,Medline and EMBase,randomized controlled trials(RCT)about the efficacyof Yixinshu capsule(test group)versus other drugs (control group) in the adjuvant treatment of angina pectoris were collected. Meta-analysis was performed bu using Rev Man 5.2 software after data extraction and quality evaluation by modified Jadad. RESULTS:Totally 11 RCTs were enrolled,involving 1 827 pa-tients. Results of Meta-analysis showed the total effective rate of angina pectoris improvement [OR=0.30,95%CI(0.23,0.40),P<0.001] and electrocardiogram improvement [OR=0.52,95%CI(0.41,0.66),P<0.001] in test group were significantly higher than control group,there was significant difference between 2 groups. CONCLUSIONS:Yixinshu is effective for the adjuvant treatment of angina pectoris.
10.Investigation of Medical Staff's Recognition of ADR Monitoring
Guilan JIN ; Lijun LIANG ; Qiuping PAN ; Xiangfei XING
China Pharmacy 2005;0(14):-
OBJECTIVE:To get to know medical staff's recognition of ADR monitoring in our city.METHODS:The concept,reporting consciousness,range and reasons for ADR reporting,reporting processes,professional organization of ADR and law consciousness of ADR etc.were investigated in400medical staff members through questionnaires on“Medical Staff's Recognition Degree to the Monitoring of ADR”.RESULTS:The medical staff in our city were basically clear about the range and the reasons for ADR reporting,but they lacked adequate recognition to the concept and the consciousness of ADR report?ing,they were not clear about the reporting processes and the organization of ADR and they lack the law consciousness of ADR reporting.CONCLUSION:It is necessary to carry out training on professional knowledge,laws and regulations of ADR among the medical staff so as to enhance their recognition to ADR monitoring and to make ADR monitoring as a self-conscious behavior.